SOURCE READING
Original and translation
The excerpt and translation use the primary source below. Further references inform SHIO’s analysis.
Primary source
- Original title
- Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics
- Original author / institution
- U.S. Food and Drug Administration — Oncology Center of Excellence; CDER; CBER
- Primary source
- U.S. Food and Drug Administration
- Source language
- English
- Original publication date
- Original publication date not provided
An excerpt from the introduction to FDA’s December2018 guidance, not the full document. The source gives a month and year; no exact publication day is invented. Copy verified on October20,2026. SHIO analysis is separate.
Basis for use：FDA public-domain text; third-party exceptions apply
This edition uses the source language, so the original appears once.
This guidance provides recommendations to applicants on endpoints for cancer clinical trials submitted to the Food and Drug Administration (FDA) to support effectiveness claims in new drug applications (NDAs), biologics license applications (BLAs), or supplemental applications. It also provides background information and discusses general regulatory principles. The endpoints discussed in this guidance are for drugs to treat patients with an existing cancer. This guidance does not address endpoints for drugs to prevent or decrease the incidence of cancer.SHIO analysis
A trial endpoint defines what the result can answer
The following is SHIO’s independent judgment and discussion of methods. It is separate from the source text and its translation.
SHIO reading note
Before asking whether a study found a significant difference, ask what it measured. FDA’s oncology endpoint guidance and surrogate endpoint resources offer a foundation for examining the connection between a research purpose and its reported result.
The central idea
SHIO treats an endpoint as a contract between purpose and measurement. The question, recorded change and public claim should remain connected throughout a project.
Separate measurement from the final purpose
FDA distinguishes clinical outcomes concerning how people feel, function or survive from surrogate endpoints used in their place. A surrogate does not directly measure the clinical benefit of primary interest; its predictive role needs supporting evidence within a context of use.
SHIO proposes writing three statements for every claim: what the research aims to improve, what the trial actually measures and what supports the connection. A biomarker change should not automatically become an overall patient benefit. Explicit reasoning is more useful than a vague qualification appended to a headline.
Read the guidance boundary too
The oncology guidance used here is dated December 2018, with no exact publication day supplied. It covers treatment of existing cancer rather than cancer prevention and describes its recommendations as nonbinding. This is a reading of historical guidance, not an announcement of a new rule.
SHIO would preserve endpoint definitions, measurement schedules and analysis plans at project initiation, recording the reasons for changes. This is an operating proposal, not a substitute for verifying requirements applicable to a particular development programme or communicating with the relevant review authority.
Bring the whole result into the judgment
Public explanations should let readers locate the population, comparator, observation period, missing information and unfavourable findings. SHIO offers these checks to bring a word such as effective back to a question that can be examined. No single statistic should carry an entire study’s interpretation.
Organisational incentives matter too. A review process focused on one impressive metric may lose sight of its original purpose. SHIO proposes requiring the conditions supporting a conclusion and the gap the next study must address within the same deliverable. Evidence boundaries should survive the editing process.
A question for practice
SHIO values results that remain open to questions: what was measured, how it connects to the purpose and what evidence is still missing. Understanding endpoints does not replace individual medical judgment or establish comparisons between separate trials and products.
Research limits: findings depend on the study population and methods and do not establish an individual treatment benefit. This essay examines research and does not provide diagnosis or treatment advice.
REFERENCES & EDITORIAL NOTE
Sources & further reading
The source’s original title, author and basis for use appear in the source section. Excerpts, SHIO translations and independent analysis are clearly separated. References include the primary source and supporting material for checking the evidence and its context.
U.S. Food and Drug Administration · Primary source
Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics
Original source date：No publication date providedAccessed：FDA Website Policies, Linking to or Copying Information on the FDA Website, states that unless otherwise noted FDA website text and graphics are public domain and may be freely republished. These selected passages are institutional FDA news/guidance text, not externally authored quotations, and carry no separate copyright notice. No FDA images, logos or external papers are reproduced. Source links and copy date are retained. Policy/source: https://www.fda.gov/about-fda/about-website/website-policies Selected original excerpt and SHIO translation only, not full reproduction. No institutional endorsement.
U.S. Food and Drug Administration
Surrogate Endpoint Resources for Drug and Biologic Development
Original source date：No publication date providedAccessed：FDA website content is public domain unless otherwise noted; verified against FDA Website Policies. Original editorial analysis, no full translation; no FDA endorsement.
U.S. Food and Drug Administration
Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics: Guidance for Industry (December 2018)
Original source date：No publication date providedAccessed：FDA website content is public domain unless otherwise noted; verified against FDA Website Policies. Original editorial analysis, no full translation; no FDA endorsement.